The Lost Generation: Weak Progeny From Pfizer And Wyeth R&D
This article was originally published in The Pink Sheet Daily
An update on the drugs that were supposed to be the stars of a new generation of Pfizer and Wyeth products.
You may also be interested in...
Combination of Pfizer and Wyeth would create a drug powerhouse with combined sales of over $70 billion, strengthen Pfizer’s position in biotech and vaccines and create billions in cost savings opportunities.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.